In today’s session Aerie Pharmaceuticals Inc (AERI) registered an unusually high (747) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the October, 2016 call, expecting serious AERI increase. With 747 contracts traded and 21964 open interest for the Oct, 16 contract, it seems this is a quite bullish bet. The option with symbol: AERI161021C00040000 closed last at: $1.5 or 6.3% down. The stock increased 0.84% or $0.32 during the last trading session, hitting $38.33. About 747,119 shares traded hands. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 117.41% since March 2, 2016 and is uptrending. It has outperformed by 108.17% the S&P500.
Analysts await Aerie Pharmaceuticals Inc (NASDAQ:AERI) to report earnings on November, 1. They expect $-0.73 earnings per share, down 5.80% or $0.04 from last year’s $-0.69 per share. After $-0.87 actual earnings per share reported by Aerie Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -16.09% EPS growth.
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Ratings Coverage
Out of 9 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 9 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aerie Pharmaceuticals has been the topic of 17 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) earned “Buy” rating by Cantor Fitzgerald on Thursday, September 15. The firm has “Strong Buy” rating by Raymond James given on Wednesday, September 14. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, September 17. The company was maintained on Thursday, September 15 by RBC Capital Markets. Stifel Nicolaus maintained Aerie Pharmaceuticals Inc (NASDAQ:AERI) on Thursday, September 17 with “Buy” rating. Cantor Fitzgerald maintained the shares of AERI in a report on Friday, August 7 with “Buy” rating. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, November 4. As per Wednesday, September 9, the company rating was initiated by JMP Securities. On Thursday, September 15 the stock rating was maintained by Needham with “Buy”. H.C. Wainwright initiated it with “Buy” rating and $66 target price in Tuesday, September 20 report.
Insitutional Activity: The institutional sentiment increased to 1.67 in 2016 Q2. Its up 0.28, from 1.39 in 2016Q1. The ratio increased, as 11 funds sold all Aerie Pharmaceuticals Inc shares owned while 22 reduced positions. 9 funds bought stakes while 46 increased positions. They now own 26.15 million shares or 2.97% more from 25.39 million shares in 2016Q1.
Group Inc holds 0% or 13,864 shares in its portfolio. Teachers Retirement Of The State Of Kentucky accumulated 33,410 shares or 0.01% of the stock. Rhumbline Advisers holds 0% or 22,960 shares in its portfolio. Gsa Capital Prns Limited Liability Partnership holds 12,437 shares or 0.01% of its portfolio. Endurant Limited Partnership has invested 0.2% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Partner L P last reported 44,345 shares in the company. Teachers Inc has 38,197 shares for 0% of their US portfolio. Raymond James Assocs holds 52,563 shares or 0% of its portfolio. Boulegeris Investments Incorporated holds 1.1% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 91,770 shares. Northpointe Llc owns 481,769 shares or 1% of their US portfolio. Swiss Natl Bank, a Switzerland-based fund reported 38,200 shares. State Street Corporation accumulated 593,978 shares or 0% of the stock. The United Kingdom-based Barclays Public Limited Com has invested 0% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Moreover, Manchester Ltd Liability Corp has 0% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 150 shares. Dafna Limited Co accumulated 2.24% or 160,869 shares.
Insider Transactions: Since July 22, 2016, the stock had 1 insider buy, and 0 insider sales for $4.38 million net activity. 250,000 shares with value of $4.38M were bought by Foresite Capital Management II – LLC on Friday, July 22.
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The company has a market cap of $1.13 billion. The Firm is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. It currently has negative earnings. The Company’s primary product candidates are Rhopressa and Roclatan.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.